Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
On April 7, 2022, Neoleukin Therapeutics (NASDAQ:NLTX) announced that its CEO, Jonathan Drachman, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference on April 14, 2022, at 12:00 p.m. Eastern.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On April 7, 2022, Neoleukin Therapeutics (NASDAQ:NLTX) announced that its CEO, Jonathan Drachman, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference on April 14, 2022, at 12:00 p.m. Eastern. The event will be accessible via a webcast on Neoleukin's website, with an archived replay available for 30 days post-event. Neoleukin is focusing on developing next-generation immunotherapies for cancer and autoimmune conditions through advanced protein design technology, notably its lead candidate, NL-201.
Details
News Market Reaction – NLTX
The recorded move for NLTX in the trading session of this news was -1.03%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference on Thursday, April 14, 2022 at 12:00 p.m. Eastern.
The webcast presentation can be accessed from the investors section of the Neoleukin website at http://investor.neoleukin.com/events. An archived replay will also be available on the company website for at least 30 days following the event.
About Neoleukin Therapeutics, Inc.
Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.
Contacts:
Media
Julie Rathbun
206-769-9219
jrathbun@neoleukin.com
Investors
Solebury Trout
Alexandra Roy
617-221-9197
aroy@soleburytrout.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.